WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia

Leukemia

Volumn 21, Issue 7, 2007, Pages 1442-1450

  Cilloni, D ^a   Messa, F ^a   Martinelli, G ^b   Gottardi, E ^a   Arruga, F ^a   Defilippi, I ^a   Carturan, S ^a   Messa, E ^a   Fava, M ^a   Giugliano, E ^a   Rosso, V ^a   Catalano, R ^a   Merante, S ^c   Nicoli, P ^a   Rondoni, M ^b   Ottaviani, E ^b   Soverini, S ^b   Tiribelli, M ^d   Pane, F ^e   Baccarani, M ^b   Saglio, G ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; HYDROXYUREA; IMATINIB; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC CODE; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

EID: 34250716883     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404670     Document Type: Article

References (37)

1. Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7: 21-25.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-2779.
3. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med: 2003; 54: 169-184.
4. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol: 1992; 99:: 90-94.
5. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341: 1112-1120.
6. Luppi M, Marasca R, Morselli M, Brozzi P, Torelli G. Clonal nature of hypereosinophilic syndrome. Blood 1994; 84: 349-350.
7. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999; 93: 1651-1657.
8. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
9. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359: 1577-1578.
10. Coutre S, Gotlib J. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol 2004; 4: 307-315.
11. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038-3045.
12. Stone RM, Gilliland DG, Klion AD. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Semin Oncol 2004; 31: 12-17.
13. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DJ, Coutre SE. The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2888.
14. Bigoni R, Cuneo A, Roberti MG, Dilani R, Bardi A, Cavazzini F et al. Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome. Haematologica 2000; 85: 486-491.
15. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968; 68: 1220-1229.
16. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520.
17. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005; 19: 1318-1323.
18. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M et al. Significant correlation between the degree of WT1 expression level and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21: 1988-1995.
19. Inoue K, Ogawa H, Sonoda Y, Kimura T, sakabe H, Oka Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukaemia. Blood 1997; 89: 1405-1412.
20. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115-2121.
21. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267-2278.
22. Cilloni D, Saglio G. Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukaemia patients undergoing Imatinib therapy. Semin Hematol 2003; 40: 37-41.
23. Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003; 78: 349-356.
24. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698-1704.
25. Bain B, Pierre R, Imbert M. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In: IARC (ed) World Health Organization Classification of Tumors: Tumours of the hematopoietic and lymphoid tissues. International Agency for Research in Cancer (IARC) Press: Lyon, France, 2001.
26. Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
27. Cilloni D, Gottardi E, Saglio E. WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Myeloid Leukemia: Methods and Protocols 2005; 125: 199-211.
28. Tefferi A, Patnaik MA, Pardanani A. Eosinophilia: Secondary, clonal and idiopathic. Br J Haematol 2006; 133: 468-492.
29. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Perla G, Minervini MM et al. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis. Leuk Lymphoma 2004; 45: 1219-1222.
30. Mitelman F, Panani A, Brandt L. Isochromosome 17 in a case of eosinophilic leukaemia. An abnormality common to eosinophilic and neutrophilic cells. Scand J Haematol 1975; 14: 308-312.
31. Needleman SW, Mane SM, Gutheil JC, Kapil V, Heyman MR, Testa JR. Hypereosinophilic syndrome with evolution to myeloproliferative disorder: Temporal relationship to lossof y chromosome and c-N-ras activation. Hematol Pathol 1990; 4: 149-155.
32. Sjoblom T, Boureux A, Ronnstrand L, Heldin CH, Ghysdael J, Ostman A. Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF betaR fusion protein. Oncogene 1999; 18: 7055-7062.
33. Haber DA, Buckler AJ. WT1: A novel tumor suppressor gene inactivated in Wilms' tumor. New Biol 1992; 4: 97-106.
34. Haber DA, Housman DE. Role of the WT1 gene in Wilms' tumour. Cancer Surv 1992; 12: 105-117.
35. Baird PN, Simmons PJ. Expressin of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25: 312-320.
36. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue H et al. The Wilms' tumor gene is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13: 393-399.
37. Shichishima T, Okamoto M, Ikeda K, Kaneshige T, Sugiyama H, Terasawa T et al. HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 2002; 100: 22-28.